Vaxart, Inc. (OTC: VXRT) is a Healthcare company (Biotechnology) with a market capitalization of $87M. The Maz Rating grades it against the other companies in its sector.
Vaxart, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.35, Vaxart, Inc. trades at 3.0x trailing earnings, 0.5x sales and 1.3x book value, with an EV/EBITDA of 1.6. Over the last twelve months it generated about $182M of revenue and $29M of net income. It runs a gross margin of 99.3%, an operating margin of 16.6% and a net margin of 16.0%. It shows return on equity of 35.1%, return on invested capital of 55.4% and a free cash flow yield of 36.9%. On the balance sheet: a debt-to-equity ratio of 0.11 and a current ratio of 1.30. Over the past 52 weeks the share price ranged from $0.33 to $0.84, with a beta of 1.06.
Vaxart, Inc. does not currently pay a dividend.
3 Wall Street analyst ratings cover the stock: 3 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.